Progressive multifocal leukoencephalopathy epidemiology and demographics
|
Progressive multifocal leukoencephalopathy Microchapters |
|
Differentiating Progressive multifocal leukoencephalopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Progressive multifocal leukoencephalopathy epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Progressive multifocal leukoencephalopathy epidemiology and demographics |
|
FDA on Progressive multifocal leukoencephalopathy epidemiology and demographics |
|
CDC on Progressive multifocal leukoencephalopathy epidemiology and demographics |
|
Progressive multifocal leukoencephalopathy epidemiology and demographics in the news |
|
Blogs on Progressive multifocal leukoencephalopathy epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Epidemiology and Demographics
About 2-5% of AIDS patients develop PML. It is unclear why PML occurs more frequently in AIDS than in other immunosuppressive conditions; some research suggests that the effects of HIV on brain tissue, or on JCV itself, make JCV more likely to become active in the brain and increase its damaging inflammatory effects (Berger, 2003).
There are case reports of PML being caused by pharmacological agents, although there is some speculation this could be due in part to the existing impaired immune response or 'pharm combos' rather than individual drugs. Rituxan and Natalizumab (branded Tysabri).